Tuesday, April 20, 2021 |

Maryland biotech earns FDA approval for pediatric ADHD drug

April 7, 2021
pill, capsule, medicine

Supernus Pharmaceuticals Inc. has earned a regulatory approval for its attention deficit hyperactivity disorder drug for pediatric patients, ending a monthslong back-and-forth with the agency over the product and opening the door for the Rockville company to take it to market. The Food and Drug Administration greenlighted Qelbree, an ADHD treatment for kids and adolescents ages 6 to 17, after four late-stage trials with more than 1,000 patients in that age group, the biotech said Friday after the closing bell.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.